-
China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste
•
The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released the “Implementation Plan for Saving Drug Resources and Curbing Drug Waste,” an initiative aimed at streamlining measures across drug production, clinical medication, distribution, public education, waste management, and organizational enforcement. Promoting Prudent Drug Packaging and…
-
China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities
•
The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued comprehensive guidelines aimed at bolstering the construction of compact county-level medical care communities. The initiative seeks to enhance the efficiency of medical resource allocation and utilization, synchronize the development and governance of medical insurance, healthcare,…
-
Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology
•
Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative diagnostic technology from UK-headquartered LumiraDx (OTCMKTS: LMDXF). The transaction, expected to close in mid-2024, involves an upfront payment of $295 million, complemented by up to an additional $55 million to support LumiraDx’s point-of-care business during…
-
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
•
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd., (SHE: 000963) regarding their joint development of the type 2 diabetes drug TTP273. Huadong, confirming the cancellation, stated that TTP273 was found to be inferior to its own drug candidate, HDM1002. TTP273, a first-in-class, non-peptide,…
-
Roche Secures Diagnostics Deal with LumiraDx for $295M
•
Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology from UK-based LumiraDx. The transaction, valued at $295 million, is anticipated to conclude in mid-2024, with an additional payment of up to $55 million to cover LumiraDx’s point-of-care business expenses until the deal’s closure. The…
-
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
•
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based Huadong Medicine Co., Ltd (SHE: 000963) regarding their collaboration on the type 2 diabetes drug TTP273. Huadong confirmed the news, stating that TTP273 was considered inferior to its in-house developed drug HDM1002. TTP273, a first-in-class…
-
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results from the first-in-human (FIH) study for its novel adjuvanted recombinant shingles vaccine, REC610, which is being conducted in the Philippines. The study uses GlaxoSmithKline’s Shingrix (recombinant zoster vaccine; RZV), a major UK pharmaceutical company’s shingles…
-
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
•
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first patient dosing in the Phase III GLORY-2 study, which is assessing the higher dose 9mg version of mazdutide (IBI362) for the treatment of obesity in Chinese adults. Mazdutide is a dual agonist drug candidate targeting…
